HK Stock MarketDetailed Quotes

CSTONE PHARMA-B (02616)

Watchlist
  • 8.060
  • +0.190+2.41%
Trading May 22 09:30 CST
12.90BMarket Cap-26.69P/E (TTM)

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

CSTONE PHARMA-B (02616) Revenue Breakdown Overview

By Business/Source

Currency:CNY
2025/FY
Stock NameRevenueRatio
Authorization fee income167.66M62.19%
Sale of drugs78.35M29.06%
Royalty income23.58M8.75%

By Product

Currency:CNY
2025/FY
Stock NameRevenueRatio
Authorization fee income167.66M62.19%
Sale of drugs78.35M29.06%
Royalty income23.58M8.75%

By Country/Region

Currency:CNY
2025/FY
Stock NameRevenueRatio
Outside mainland China185.74M68.90%
China Mainland83.84M31.10%

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Market Insights
Petroleum
No. Symbol 20D % Chg
Sample Name
Sample Code
 +4.98%
Sample Name
Sample Code
 +0.45%
Sample Name
Sample Code
 -1.11%
4
KUNLUN ENERGY
00135
-4.16%
5
CHINA OILFIELD
02883
-4.39%
View More
No. Symbol 20D % Chg
Sample Name
Sample Code
 +35.71%
Sample Name
Sample Code
 +28.58%
Sample Name
Sample Code
 +14.20%
4
Emdoor Information
001314
+13.75%
5
Business-intelligence Of Oriental Nations Corporation
300166
+13.50%
View More
China and the US begin implementing the Kuala Lumpur economic and trade consultation consensus.
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -